December 1, 2020
Donald Lynch, MD, assistant professor of cardiovascular health and disease in the University of Cincinnati College of Medicine, is partnering with researchers in Missouri and Georgia to create a smartphone app that delivers COVID-19 information tailored to Black communities.
September 28, 2020
Richard Becker, MD, and Duncan Hite, MD, both professors in the UC College of Medicine and UC Health physicians, spoke with WVXU reporter Ann Thompson about a phase 2 clinical trial underway at UC/UC Health to determine the safety and efficacy of the drug razuprotafib in treating COVID-19 patients. UC is one of 20 sites across the nation participating in the trial.
November 15, 2020
Donald Lynch, MD, assistant professor in the UC Division of Cardiovascular Health and Disease, is developing a smartphone app designed to provide better information and education that will reach African-American communities which are disproportionately affected by the COVID-19 pandemic.
February 14, 2021
Yashu Dhamija, MD, a first-year fellow in the University of Cincinnati Department of Immunology, Allergy and Rheumatology, speaks with Yahoo Life about his latest research. The immunologist describe a case study of a patient who developed contact dermatitis after wearing facemasks during the COVID-19 pandemic.
March 10, 2021
A University of Cincinnati rheumatologist weighs in as the German Society for Rheumatology updates its guidelines to reflect the impact of the COVID-19 pandemic.
July 4, 2020
UC digestive diseases expert Kenneth Sherman, MD, PhD, discusses study showing COVID-19 patients in China shown mildly elevated liver enzyme levels.
September 14, 2020
Carl Fichtenbaum, MD, was interviewed by CNN for a story they published about a delay in the Astra-Zeneca COVID-19 vaccine trial.
April 14, 2022
A report published recently in JAMA Open Network finds there's a strong likelihood that the antidepressant fluvoxamine (Luvox) may moderately lower rates of hospitalization due to COVID-19 in unvaccinated patients. However, outside experts cited by Medscape differ over whether the evidence from just three studies is strong enough to warrant adding the drug to the COVID-19 armamentarium. One of those experts sources is Carl Fichtenbaum, MD, of the Division of Infectious Diseases at the UC College of Medicine.